MAPT and Alzheimer disease: In contrast to the other three primary targets considered in previous sections of this review, ApoE has the potential to influence multiple pathogenic pathways in AD, and although ApoE can and does aggregate, the opportunities for drugging ApoE go beyond the strategies discussed for Aβ, tau and ⍺Syn (Fig. 2).